Appeals court sides with Amgen over Roche anemia drug patent infringement
WASHINGTON Amgen won a case against Roche over a drug for anemia that the latter has tried to get into the United States market in a U.S. appeals court Friday, affirming an Oct. 3 decision by a federal judge in Boston.
Amgen said that Roche’s drug Mircera (methoxy polyethylene glycol-epoetin beta) infringed on its patents for the drugs Aranesp (darbepoetin alfa) and Epogen (epoetin alfa). Mircera is on the market in Europe, and the Food and Drug Administration approved it for the U.S. market in 2007.
“Amgen is pleased that the Court of Appeals has affirmed the preliminary injunction barring Roche from selling its [peg-erythropoietin] product in the United States in violation of Amgen’s erythropoietin patents,” Thousand Oaks, Calif.-based Amgen said in a statement.
Shopko donates school supplies to Green Bay area elementary school
GREEN BAY, Wis. An elementary school in Green Bay received a variety of school supplies from a locally headquartered retail chain.
Shopko announced Oct. 2 that it had donated the supplies to Sunrise River Elementary, which serves students in second through fifth grade. The supplies included basic items from the school’s required supply list.
Shopko operates stores throughout the Midwest and West.
ARCA Biopharma makes unprecedented payment to Aeolus following FDA approval of bucindolol
NEW YORK Aeolus Pharmaceuticals announced Friday that it had received a $175,000 milestone payment from ARCA Biopharma following the Food and Drug Administration’s acceptance of an approval application for a cardiovascular drug.
Aeolus said the drug, bucindolol, could be the first genetically targeted cardiovascular therapy. CPEC, a company owned jointly by Aeolus and Indevus Pharmaceuticals, licensed all rights to bucindolol to ARCA.
“ARCA’s success in demonstrating the potential benefits of bucindolol in treating heart failure in patients is encouraging,” Aeolus president and chief executive officer John McManus said in a statement. “We look forward to an expeditious review and hope for a positive outcome.”